Formulation of novel dry powder inhalation for fluticasone propionate and salmeterol xinafoate with capsule-based device

Abstract

The aim of this study was to develop a novel fluticasone propionate (FP) and salmeterol xinafoate (SX)-loaded dry powder inhaler (DPI) system, which was composed of powder formulation and performance. The air flow resistances were determined with various types of DPI device, showing that the modified RS01 device gave the specific resistance similar to the commercial DPI device. The particle properties of FP, SX, and inhalation grade lactose particles, such as particle size, size distribution, and fine content, were assessed. Subsequently, the aerodynamic behaviors of the DPI powder formulations were evaluated by the in vitro deposition of drugs in the DPI products using Andersen cascade impactor. Amongst the DPI powder formulations tested, the formulation composed of FP, SX, Respitose^® SV003, Respitose^® SV010, and Respitose^® ML006 at the weight ratio of 0.5/0.145/19/19/2 gave depositions, emitted dose, fine particle dose, fine particle fraction, and mass median aerodynamic diameter of drugs similar to the commercial product, suggesting that they had similar aerodynamic behaviors. Furthermore, it gave excellent content uniformity. Thus, this DPI using the modified RS01 device would be recommended as a candidate for FP and SX-loaded pharmaceutical DPI products.

Keywords:

• Dry powder inhaler
• fluticasone propionate
• salmeterol xinafoate
• lactose
• powder formulation
• deposition

Disclosure statement

The authors report no declarations of interest.

Additional information

Funding

This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MEST) [No. 2015R1A2A2A05027872], Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education [2016R1A6A3A01008005] and a grant [16173MFDS542] from Ministry of Food and Drug Safety in 2016.